Biotron Limited (BIT.AX)
AUD 0.02
(-5.88%)
AUD 0.02
(-5.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -5.04 Million AUD | -3.37% |
| 2023 | -4.87 Million AUD | -82.72% |
| 2022 | -2.73 Million AUD | 35.97% |
| 2021 | -4.55 Million AUD | -6.78% |
| 2020 | -4.27 Million AUD | -44.8% |
| 2019 | -2.67 Million AUD | -72.73% |
| 2018 | -3.2 Million AUD | 63.53% |
| 2017 | -4.69 Million AUD | -1.76% |
| 2016 | -4.53 Million AUD | 2.69% |
| 2015 | -4.37 Million AUD | 9.06% |
| 2014 | -3.07 Million AUD | 1.6% |
| 2013 | -4.73 Million AUD | -60.46% |
| 2012 | -2.36 Million AUD | -28.08% |
| 2011 | -1.89 Million AUD | -27.2% |
| 2010 | -1.84 Million AUD | -5.57% |
| 2009 | -1.72 Million AUD | 23.67% |
| 2008 | -1.84 Million AUD | 29.66% |
| 2007 | -3.33 Million AUD | -10.89% |
| 2006 | -2.11 Million AUD | -20.43% |
| 2005 | -1.74 Million AUD | 24.92% |
| 2004 | -3.32 Million AUD | -36.34% |
| 2003 | -2.44 Million AUD | -46.06% |
| 2002 | -1.81 Million AUD | -9.43% |
| 2001 | -1.52 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.94 Million AUD | 0.0% |
| 2024 FY | - AUD | -2.31% |
| 2024 Q4 | -2.11 Million AUD | 0.0% |
| 2023 FY | - AUD | -82.72% |
| 2023 Q2 | -2.14 Million AUD | 0.0% |
| 2023 Q4 | -2.76 Million AUD | 0.0% |
| 2022 Q2 | -1.87 Million AUD | 0.0% |
| 2022 FY | - AUD | 35.97% |
| 2022 Q4 | -818.81 Thousand AUD | 0.0% |
| 2021 Q4 | -2.18 Million AUD | 0.0% |
| 2021 Q2 | -2.4 Million AUD | 0.0% |
| 2021 FY | - AUD | -6.78% |
| 2020 Q4 | -2.3 Million AUD | 0.0% |
| 2020 Q2 | -2.04 Million AUD | 0.0% |
| 2020 FY | - AUD | -44.8% |
| 2019 Q4 | -1.41 Million AUD | 0.0% |
| 2019 FY | - AUD | -72.73% |
| 2019 Q2 | -271.63 Thousand AUD | 0.0% |
| 2018 Q2 | -163.68 Thousand AUD | 0.0% |
| 2018 Q4 | -1.43 Million AUD | 0.0% |
| 2018 FY | - AUD | 63.53% |
| 2017 Q2 | -2.02 Million AUD | 0.0% |
| 2017 FY | - AUD | -1.76% |
| 2017 Q4 | -1.08 Million AUD | 0.0% |
| 2016 Q2 | -2.8 Million AUD | 0.0% |
| 2016 Q4 | -257.39 Thousand AUD | 0.0% |
| 2016 FY | - AUD | 2.69% |
| 2015 Q4 | -560.32 Thousand AUD | 0.0% |
| 2015 FY | - AUD | 9.06% |
| 2015 Q2 | -2.19 Million AUD | 0.0% |
| 2014 Q4 | -493.18 Thousand AUD | 0.0% |
| 2014 Q2 | -2.65 Million AUD | 0.0% |
| 2014 FY | - AUD | 1.6% |
| 2013 Q3 | -960.63 Thousand AUD | 60.85% |
| 2013 FY | - AUD | -60.46% |
| 2013 Q2 | -2.45 Million AUD | -314.65% |
| 2013 Q1 | -591.79 Thousand AUD | 0.0% |
| 2013 Q4 | -1.6 Million AUD | -66.6% |
| 2012 Q1 | -473.27 Thousand AUD | 0.0% |
| 2012 Q2 | -591.79 Thousand AUD | -25.04% |
| 2012 Q4 | -591.79 Thousand AUD | 0.0% |
| 2012 FY | - AUD | -28.08% |
| 2012 Q3 | -591.79 Thousand AUD | 0.0% |
| 2011 FY | - AUD | -27.2% |
| 2011 Q4 | -473.27 Thousand AUD | 0.0% |
| 2011 Q1 | -462.28 Thousand AUD | 0.0% |
| 2011 Q2 | -473.27 Thousand AUD | -2.38% |
| 2011 Q3 | -473.27 Thousand AUD | 0.0% |
| 2010 Q1 | -432.09 Thousand AUD | 0.0% |
| 2010 FY | - AUD | -5.57% |
| 2010 Q4 | -462.28 Thousand AUD | 0.0% |
| 2010 Q3 | -462.28 Thousand AUD | 0.0% |
| 2010 Q2 | -462.28 Thousand AUD | -6.99% |
| 2009 Q4 | -432.09 Thousand AUD | 0.0% |
| 2009 Q1 | -460.41 Thousand AUD | 0.0% |
| 2009 Q2 | -432.09 Thousand AUD | 6.15% |
| 2009 Q3 | -432.09 Thousand AUD | 0.0% |
| 2009 FY | - AUD | 23.67% |
| 2008 FY | - AUD | 29.66% |
| 2008 Q4 | -460.41 Thousand AUD | 0.0% |
| 2008 Q1 | -795.62 Thousand AUD | 0.0% |
| 2008 Q2 | -460.41 Thousand AUD | 42.13% |
| 2008 Q3 | -460.41 Thousand AUD | 0.0% |
| 2007 Q1 | -528.98 Thousand AUD | 0.0% |
| 2007 Q4 | -795.62 Thousand AUD | 0.0% |
| 2007 FY | - AUD | -10.89% |
| 2007 Q2 | -795.62 Thousand AUD | -50.41% |
| 2007 Q3 | -795.62 Thousand AUD | 0.0% |
| 2006 Q1 | -907.37 Thousand AUD | 0.0% |
| 2006 Q4 | -528.98 Thousand AUD | 0.0% |
| 2006 Q3 | -528.98 Thousand AUD | 0.0% |
| 2006 Q2 | -528.98 Thousand AUD | 41.7% |
| 2006 FY | - AUD | -20.43% |
| 2005 Q2 | -907.37 Thousand AUD | -9.0% |
| 2005 FY | - AUD | 24.92% |
| 2005 Q3 | -907.37 Thousand AUD | 0.0% |
| 2005 Q1 | -832.42 Thousand AUD | 0.0% |
| 2005 Q4 | -907.37 Thousand AUD | 0.0% |
| 2004 Q2 | -832.42 Thousand AUD | 31.65% |
| 2004 Q4 | -832.42 Thousand AUD | 0.0% |
| 2004 Q1 | -1.21 Million AUD | 0.0% |
| 2004 FY | - AUD | -36.34% |
| 2004 Q3 | -832.42 Thousand AUD | 0.0% |
| 2003 Q2 | -1.21 Million AUD | -39.87% |
| 2003 FY | - AUD | -46.06% |
| 2003 Q3 | -1.21 Million AUD | 0.0% |
| 2003 Q1 | -870.7 Thousand AUD | 0.0% |
| 2003 Q4 | -1.21 Million AUD | 0.0% |
| 2002 FY | - AUD | -9.43% |
| 2002 Q1 | -638.55 Thousand AUD | 0.0% |
| 2002 Q3 | -870.7 Thousand AUD | 0.0% |
| 2002 Q2 | -870.7 Thousand AUD | -36.36% |
| 2002 Q4 | -870.7 Thousand AUD | 0.0% |
| 2001 Q2 | -638.55 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | - AUD | 0.0% |
| 2001 Q4 | -638.55 Thousand AUD | 0.0% |
| 2001 Q3 | -638.55 Thousand AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 148.577% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -246.0% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 86.169% |
| Biome Australia Limited | -1.57 Million AUD | -219.344% |
| Patrys Limited | -3.49 Million AUD | -44.325% |
| Orthocell Limited | -11.68 Million AUD | 56.853% |
| Imugene Limited | -147.97 Million AUD | 96.594% |
| Noxopharm Limited | -5.94 Million AUD | 15.229% |
| PYC Therapeutics Limited | -38.11 Million AUD | 86.778% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 55.397% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 29.86% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 36.099% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 49.347% |
| CSL Limited | 4.73 Billion AUD | 100.106% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 42.942% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -69.414% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 109.718% |
| Starpharma Holdings Limited | -12.57 Million AUD | 59.926% |
| Nanollose Limited | -1.14 Million AUD | -339.067% |
| Memphasys Limited | -3.3 Million AUD | -52.372% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -599.579% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -180.582% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -10.537% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 63.791% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -78.845% |
| Race Oncology Limited | -14.2 Million AUD | 64.515% |
| Nyrada Inc. | -4.59 Million AUD | -9.657% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 121.946% |
| Dimerix Limited | -24.95 Million AUD | 79.806% |
| PharmAust Limited | -9.45 Million AUD | 46.676% |
| Immutep Limited | -42.87 Million AUD | 88.245% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 88.711% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 74.248% |
| BTC Health Limited | 1.05 Million AUD | 577.6% |
| Acrux Limited | -7.93 Million AUD | 36.451% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 102.529% |
| Tissue Repair Ltd | -5.77 Million AUD | 12.726% |
| AdAlta Limited | -5.3 Million AUD | 4.953% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 88.893% |
| Hexima Limited | -995.54 Thousand AUD | -406.262% |
| AnteoTech Limited | -11.57 Million AUD | 56.442% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 92.191% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 76.398% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -55.437% |
| Actinogen Medical Limited | -12.92 Million AUD | 60.994% |
| Immuron Limited | -6.19 Million AUD | 18.608% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -165.603% |